Optimizing Longitudinal Tobacco Cessation Treatment in Lung Cancer Screening
JAMA Network Open · 24.08.2023 · 6 (8) · e2329903
DOI: 10.1001/jamanetworkopen.2023.29903 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, online erschienen am 24.08.2023. Verfasst von Steven S Fu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Veterans Affairs Health Services Research and Development Center for Care Delivery and Outcomes Research, Minneapolis VA Health Care System, Minneapo…. Hauptthemen laut MEDLINE: Tobacco Use Cessation, Smoking Cessation, Lung Neoplasms. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, NCATS NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Importance Nearly half of the 14.8 million US adults eligible for lung cancer screening (LCS) smoke cigarettes. The optimal smoking cessation program components for the LCS setting are unclear.
Objective
To assess the effect of adding a referral to prescription medication therapy management (MTM) to the tobacco longitudinal care (TLC) program among patients eligible for LCS who smoke and do not respond to early tobacco treatment and to assess the effect of decreasing the intensity of TLC among participants who do respond to early treatment. Design, Setting, and Participants This randomized clinical trial included patients who currently smoked cigarettes daily and were eligible for LCS. Recruitment took place at primary care centers and LCS programs at 3 large health systems in the US and began in October 2016, and 18-month follow-up was completed April 2021.
Interventions
(1) TLC comprising intensive telephone coaching and combination nicotine replacement therapy for 1 year with at least monthly contact; (2) TLC with MTM, MTM offered pharmacist-referral for prescription medications; and (3) Quarterly TLC, intensity of TLC was decreased to quarterly contact. Intervention assignments were based on early response to tobacco treatment (abstinence) that was assessed either 4 weeks or 8 weeks after treatment initiation. Main outcomes and Measures Self-reported, 6-month prolonged abstinence at 18-month.
Results
Of 636 participants, 228 (35.9%) were female, 564 (89.4%) were White individuals, and the median (IQR) age was 64.3 (59.6-68.8) years. Four weeks or 8 weeks after treatment initiation, 510 participants (80.2%) continued to smoke (ie, early treatment nonresponders) and 126 participants (19.8%) had quit (ie, early treatment responders). The 18 month follow-up survey response rate was 83.2% (529 of 636). Across TLC groups at 18 months follow-up, the overall 6-month prolonged abstinence rate was 24.4% (129 of 529). Among the 416 early treatment nonresponders, 6-month prolonged abstinence for TLC with MTM vs TLC was 17.8% vs 16.4% (adjusted odds ratio [aOR] 1.13; 95% CI, 0.67-1.89). In TLC with MTM, 98 of 254 participants (39%) completed at least 1 MTM visit. Among 113 early treatment responders, 6-month prolonged abstinence for Quarterly TLC vs TLC was 24 of 55 (43.6%) vs 34 of 58 (58.6%) (aOR, 0.54; 95% CI, 0.25-1.17). Conclusions and Relevance In this randomized clinical trial, adding referral to MTM with TLC for participants who did not respond to early treatment did not improve smoking abstinence. Stepping down to Quarterly TLC among early treatment responders is not recommended. Integrating longitudinal tobacco cessation care with LCS is feasible and associated with clinically meaningful quit rates. Trial Registration ClinicalTrials.gov Identifier: NCT02597491
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Veterans Affairs Health Services Research and Development Center for Care Delivery and Outcomes Research, Minneapolis VA Health Care System, Minneapolis, Minnesota.
- Department of Medicine, University of Minnesota, Minneapolis.
- Department of Psychology, University of Minnesota, Minneapolis.
- Division of Biostatistics, University of Minnesota, Minneapolis.
- Biostatistics Core, Masonic Cancer Center, University of Minnesota, Minneapolis.
- Survey Research Center, Institute for Social Research, University of Michigan, Ann Arbor.
Förderung
- NIDA NIH HHS
- NCATS NIH HHS
- NCI NIH HHS
Zitieren
APA
Fu, S. S., Rothman, A. J., Vock, D. M., Lindgren, B. R., Almirall, D., Begnaud, A., Melzer, A. C., Schertz, K. L., Branson, M., Haynes, D., Hammett, P., & Joseph, A. M. (2023). Optimizing Longitudinal Tobacco Cessation Treatment in Lung Cancer Screening. JAMA Network Open, 6(8), e2329903. https://doi.org/10.1001/jamanetworkopen.2023.29903
Vancouver
Fu SS, Rothman AJ, Vock DM, Lindgren BR, Almirall D, Begnaud A, et al. Optimizing Longitudinal Tobacco Cessation Treatment in Lung Cancer Screening. JAMA Network Open. 2023;6(8):e2329903. doi:10.1001/jamanetworkopen.2023.29903
BibTeX
@article{Fu2023,
author = {Fu, Steven S and Rothman, Alexander J and Vock, David M and Lindgren, Bruce R and Almirall, Daniel and Begnaud, Abbie and Melzer, Anne C and Schertz, Kelsey L and Branson, Mariah and Haynes, David and Hammett, Patrick and Joseph, Anne M},
title = {Optimizing Longitudinal Tobacco Cessation Treatment in Lung Cancer Screening},
journal = {JAMA Network Open},
year = {2023},
volume = {6},
number = {8},
pages = {e2329903},
doi = {10.1001/jamanetworkopen.2023.29903}
}
EUVIMED